The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
María-Victoria MateosDuring the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answered: Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?
Is the treatment of high-risk SMM the way for achieving the cure?
In this presentation, Mateos discusses the progression of monoclonal gammopathy of undetermined significance (MGUS) and SMM to MM from a molecular point of view. She explains the 2/20/20 risk stratification model for SMM, and the phase III clinical trials that have demonstrated a benefit in treating patients with high-risk SMM to delay the progression to overt MM. In her road map to cure MM, early treatment of SMM is a crucial step, and she presents two curative approaches being currently investigated in clinical trials.
Is the treatment of high-risk SMM the way for achieving the cure?
Is the treatment of high-risk SMM the way for achieving the cure?
María-Victoria Mateos' slides are available as a downloadable resource below.
Find below links to the other talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.
'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.
'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.